Main Inclusion Criteria (cohorts 1, 2, 3):

        • Patients with histologically confirmed, relapsed or refractory haematological
        malignancies. Patients will include but are not limited to the following: Arm A : B-cell
        Non-Hodgkin lymphoma , T-cell Non-Hodgkin lymphoma , Small lymphocytic lymphoma (SLL) ,
        Multiple myeloma (MM) Arm B: CLL (chronic lymphocytic leukaemia), Richter's syndrome ,
        AML/secondary AML, ALL , High-risk myelodysplastic syndrome (MDS), CMML (chronic
        myelomonocytic leukemia)

          -  Eastern Cooperative Oncology Group (ECOG) performance status of ≤2.

          -  Must have received at least 2 prior lines of therapy

          -  Documented active disease requiring treatment per respective NCCN/ESMO guideline that
             is relapsed or refractory defined as: Recurrence of disease after response to prior
             line(s) of therapy Or progressive disease after completion of the treatment regimen
             preceding entry into the study

          -  Adequate hematologic, hepatic and renal function

          -  Women should be using adequate contraceptive measures, should not be breast feeding
             and must have a negative pregnancy test before start of dosing if of child-bearing
             potential or must have evidence of nonchildbearing potential

          -  Men should be willing to use barrier contraception (ie, condoms) and refrain from
             sperm donation during and after the conduct of the trial.

        Main Exclusion Criteria (cohorts 1,2, 3):

          -  Treatment with any of the following: any other chemotherapy, immunotherapy or
             anticancer agents within 2 weeks, any hematopoietic growth factors (e.g., filgrastim;
             [G-CSF] or sargramostin [GM-CSF]) within 7 days of the first dose of investigational
             product or pegylated G-CSF (pegfilgrastim) or darbepoetin within 14 days, any
             full-dose level anti-coagulation treatment sufficiently prior to treatment that INR is
             <1.5 (DVT/PE prophylaxis dose is allowed) or Major surgery (excluding placement of
             vascular access) within 4 weeks (with regard to the first dose of study treatment on
             this protocol).

          -  With the exception of alopecia, any unresolved toxicities from prior therapy greater
             than CTCAE Grade 1 at the time of starting study treatment.

          -  Presence of, or history of, CNS lymphoma, leptomeningeal disease or spinal cord
             compression.

          -  History of prior nonhematologic malignancy with exceptions mentioned in protocol

          -  Undergone any procedures or experienced any of the conditions listed in protocol
             exclusion criteria currently or in the preceding 6 months

          -  Patients with any of the following: evidence of severe or uncontrolled systemic
             disease, asecretory myeloma, a known history of infection with human immunodeficiency
             virus (HIV), serological evidence of active Hepatitis B infection, cardiac
             abnormalities as mentioned in the protocol, previous allogeneic bone marrow
             transplant, adrenal gland insufficiency or pancreatitis.

          -  History of severe allergic or anaphylactic reactions to BH3 mimetics or history of
             hypersensitivity to active or inactive excipients of AZD4573.